Objective
In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progression by inhibiting maturation/expansion of pathogenic autoimmune responses through immune tolerising treatments of subjects not only in early
stages of joint inflammation (undifferentiated arthritis and early RA) but also in even earlier defined stages i.e. before onset of joint inflammation, when patients have arthralgia and/or bone loss, or sub-clinical stages of joint inflammation.
Today, no drugs are approved for these early phases of RA development, where symptoms such as pain and fatigue cause major loss of life quality and where successful interference would prevent onset of disease. Thus, an important part of our work will be to achieve a better understanding of this as yet unexplored phase of disease. In the proposed project we will develop and validate new methods to identify individuals at high risk for RA, tools to monitor disease progress and expand and further develop cohorts suitable for these purposes.
Furthermore we will validate and standardise methods to monitor immune tolerance to be used in clinical trials for tolerising therapies for RA.
The aim is thus to interfere with the specific immune reactions that contribute to RA symptoms in such a way that a specific and long-lasting therapeutic effect (ultimately a cure) is accomplished for a major proportion of RA patients and prevention of diseases is accomplished in individuals at high risk for RA.
Investigator-initiated as well as company-sponsored clinical trials in well stratified patient groups will be performed in collaboration with SMEs and/or contributing pharma companies and their immune effects studied using the same panel of biomarkers allowing for standardisation across protocols. Our ambition is also to disseminate our experiences from RA to other rheumatic and other immune-mediated diseases.
Fields of science
- medical and health scienceshealth scienceshealth care serviceseHealth
- medical and health sciencesclinical medicinerheumatology
- medical and health sciencesbasic medicineimmunology
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesmedical biotechnologycells technologies
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
17177 Stockholm
Sweden
See on map
Participants (19)
10117 Berlin
See on map
1090 Wien
See on map
WC2R 2LS London
See on map
B15 2TT Birmingham
See on map
91054 Erlangen
See on map
NE1 7RU Newcastle Upon Tyne
See on map
G12 8QQ Glasgow
See on map
2333 ZA Leiden
See on map
4072 Brisbane
See on map
1085 Budapest
See on map
3590 Diepenbeek
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
151 36 Sodertalje
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
6500 Bellinzona
See on map
2340 Beerse
See on map
1070 Bruxelles
See on map
TW89GS Brentford
See on map
65929 Frankfurt Am Main
See on map
10154 New York
See on map
CT13 9NJ Sandwich
See on map